BridgeMD
New treatment option for Peritoneal Dialysis Complication
Official title Dapagliflozin Delays the Loss of Renal Function in Peritoneal Dialysis Patients
ClinicalTrials.gov ID: NCT06398977
What this study is testing
What is Dapagliflozin?
Dapagliflozin is an investigational medicine, given as an once-daily pill taken by mouth, being studied as a potential treatment for peritoneal dialysis complication.
Also referred to as dagliflozin.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study aims to explore the role of dagliflozin in preserving the residual renal function(RRF) in peritoneal dialysis (PD) patients.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Patients with PD duration between 1 month and 3 months.
- Patients aged between 18 and 75 years.
- Voluntary signing of informed consent.
- Stable use of a maximum tolerated dose of RAAS inhibitors for one month if hypertension is present.
- Daily urine output ≥ 400ml/day.
You likely can't join if
- Pregnant and lactating women.
- Patients with type 1 diabetes mellitus.
- Patients with type 2 diabetes mellitus who have experienced diabetic ketoacidosis in the past.
- Patients with chronic liver disease, including non-alcoholic fatty liver disease, cirrhosis, ALT \> 120 IU/L, and other clinically confirmed severe...
- Patients with more than 2 episodes of urinary tract infection in the past six months.
- Patients with severe allergic reactions (rash or angioedema) to Dapagliflozin.
See the full eligibility criteria
- Patients with PD duration between 1 month and 3 months.
- Patients aged between 18 and 75 years.
- Voluntary signing of informed consent.
- Stable use of a maximum tolerated dose of RAAS inhibitors for one month if hypertension is present.
- Daily urine output ≥ 400ml/day.
- Stable PD prescription for one month.
- Pregnant and lactating women.
- Patients with type 1 diabetes mellitus.
- Patients with type 2 diabetes mellitus who have experienced diabetic ketoacidosis in the past.
- Patients with chronic liver disease, including non-alcoholic fatty liver disease, cirrhosis, ALT \> 120 IU/L, and other clinically confirmed severe liver diseases.
- Patients with more than 2 episodes of urinary tract infection in the past six months.
- Patients with severe allergic reactions (rash or angioedema) to Dapagliflozin.
- Patients using the following medications: rifampicin, phenytoin.
- Patients with malignant tumors.
- Patients who developed peritonitis within one month.
- Patients undergoing combined hemodialysis treatment.
- Patients with a willingness for kidney transplantation within six months.
- Patients with a history of pancreatitis or pancreatic transplantation.
- Patients who experienced acute coronary syndrome or cerebrovascular events within one month.
- Hemoglobin level less than 90g/L.
The study team makes the final eligibility decision.
Where it's taking place
- Chengdu, Sichuan, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Chengdu, Sichuan, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.